



Adam J. Rosenberg

OF COUNSEL

781 795 4705 direct

adam.rosenberg@faberlawgroup.com

Industry Experience

CEO

Rodin Therapeutics

Co-Founder & CEO

Teleos Therapeutics

Co-Founder & Director

Clean Membranes

Co-Founder & CEO

Link Medicine

Principal

Ovation Capital Partners

Adam helped to co-found Faber and retains a strong relationship with the firm. Leveraging his deep industry experience, Adam has advised clients on corporate financing, strategic transactions, research collaborations and academic licensing.

EXPERIENCE

Rodin Therapeutics

CEO

- Backed by leading investors, Rodin is focused on enhancing synaptic integrity to develop novel therapeutics for neurological disorders

Teleos Therapeutics

Co-Founder & CEO

- Leveraging an innovative technology platform and unique insights into zebrafish chemical biology to discover novel drug candidates for central nervous system disorders
- With core technology licensed from Massachusetts General Hospital, Teleos was founded in 2013 around strategic partnerships with leading global pharmaceutical companies

Bar Admissions

- Massachusetts
- New York

Education

- University of Virginia School of Law, J.D.
- Whittier College, B.A., *magna cum laude*

Link Medicine

Co-Founder & CEO

- Focused on discovering and developing disease-modifying neurodegenerative therapies
- Over \$50 million in equity financing raised from major institutional, strategic and high net-worth individual investors
- Growth from a largely virtual, academic research project to a science-driven, clinical stage company
- Lead program acquired by a large multinational pharmaceutical company

Adam has also served in interim executive and director roles in various emerging companies, and was a principal at Ovation Capital Partners, an early-stage technology venture capital fund based in New York. Prior to his industry experience, he was a member of the corporate finance and private equity groups of leading law firms in Boston, Seattle and New York, where he represented venture capital funds, as well as numerous venture-backed and public companies.

